The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression

International Journal of Oncology

Volumn 47, Issue 3, 2015, Pages 963-970

  Gahr, Susanne ^a,b,c   Mayr, Christian ^d   Kiesslich, Tobias ^d   Illig, Romana ^d   Neureiter, Daniel ^d   Alinger, Beate ^d   Ganslmayer, Marion ^a   Wissniowski, Till ^a,e   Di Fazio, Pietro ^f   Montalbano, Roberta ^f   Ficker, Joachim H ^b,c   Ocker, Matthias ^a,f,g   Quint, Karl ^a,f  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c Paracelsus Medical University   (Germany)

^d PARACELSUS MEDICAL UNIVERSITY   (Austria)

^e UNIVERSITY HOSPITAL MARBURG   (Germany)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g BAYER PHARMA AG   (Germany)

Author keywords

Antiangiogenesis; Connective tissue growth factor; FLT 1; Hepatocellular carcinoma; Histone deacetylase inhibitor; Histone deacetylases; KDR; LBH589; Panobinostat; Vascular endothelial growth factor

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PANOBINOSTAT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; CTGF PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INDOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; HEPG2 CELL LINE; INTRAPERITONEAL DRUG ADMINISTRATION; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; INJECTIONS, INTRAPERITONEAL; LIVER NEOPLASMS; MICE; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938082900     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3087     Document Type: Article

References (71)

1. Lodato F, Mazzella G, Festi D, Azzaroli F, Colecchia A and Roda E: Hepatocellular carcinoma prevention: A worldwide emergence between the opulence of developed countries and the economic constraints of developing nations. World J Gastroenterol 12: 7239-7249, 2006.
2. Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: Worldwide incidence and trends. Gastroenterology 127 (Suppl 1): S5-S16, 2004.
3. Peto J: Cancer epidemiology in the last century and the next decade. Nature 411: 390-395, 2001.
4. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
5. Duffy A and Greten T: Developing better treatments in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 4: 551-560, 2010.
6. Omata M, Tateishi R, Yoshida H and Shiina S: Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology 127 (Suppl 1): S159-S166, 2004.
7. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de O liveira AC, Santoro A, Raoul JL, Forner A, et al; SHARP Investigators Study Group: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
8. Okamoto K, Neureiter D and Ocker M: Biomarkers for novel targeted therapies of hepatocellular carcinoma. Histol Histopathol 24: 493-502, 2009.
9. Chan SL, Mok T and Ma BB : Management of hepatocellular carcinoma: Beyond sorafenib. Curr Oncol Rep 14: 257-266, 2012.
10. Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell 144: 646-674, 2011.
11. Sakurai T and Kudo M: Signaling pathways governing tumor angiogenesis. Oncology 81 (Suppl 1): 24-29, 2011.
12. Weis SM and Cheresh DA: Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 17: 1359-1370, 2011.
13. Ichihara E, Kiura K and Tanimoto M: Targeting angiogenesis in cancer therapy. Acta Med Okayama 65: 353-362, 2011.
14. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005.
15. Chung AS, Lee J and Ferrara N: Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514, 2010.
16. Shibuya M: Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep 41: 278-286, 2008.
17. Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC and Chen X: Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov 2: 59-71, 2007.
18. Amaoka N, Saio M, Nonaka K, Imai H, Tomita H, Sakashita F, Takahashi T , Sugiyama Y, Takami T and Adachi Y: Expression of vascular endothelial growth factor receptors is closely related to the histological grade of hepatocellular carcinoma. Oncol Rep 16: 3-10, 2006.
19. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M and Sato Y: Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-2146, 2000.
20. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
21. Schoenleber SJ, Kurtz DM, Talwalkar JA, Roberts LR and Gores GJ: Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: Systematic review and meta-analysis. Br J Cancer 100: 1385-1392, 2009.
22. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K and Shibuya M: Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann NY Acad Sci 902: 201-207, 2000.
23. Greten TF, Korangy F, Manns MP and Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 100: 19-23, 2009.
24. Carr BI, Carroll S, Muszbek N and Gondek K: Economic evaluation of sorafenib in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 25: 1739-1746, 2010.
25. Connock M, Round J, Bayliss S, Tubeuf S, Greenheld W and Moore D: Sorafenib for the treatment of advanced hepatocellular carcinoma. Health Technol Assess 14 (Suppl 1): 17-21, 2010.
26. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
27. Baeriswyl V and Christofori G: The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337, 2009.
28. Bradham DM, Igarashi A, Potter RL and Grotendorst GR: Connective tissue growth factor: A cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 114: 1285-1294, 1991.
29. Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T, Tamatani T, Tezuka K, Takemura M, Matsumura T, et al: Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126: 137-145, 1999.
30. Perbal B: NOV (nephroblastoma overexpressed) and the CCN family of genes: Structural and functional issues. Mol Pathol 54: 57-79, 2001.
31. Li MH, Sanchez T, Pappalardo A, Lynch KR, Hla T and Ferrer F: Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res 6: 1649-1656, 2008.
32. Hall-Glenn F, De Young RA, Huang BL, van Handel B, Hofmann JJ, Chen TT, Choi A, Ong JR, Benya PD, Mikkola H, et al: CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. PLoS One 7: e30562, 2012.
33. Moussad EE and Brigstock DR: Connective tissue growth factor: What's in a name? Mol Genet Metab 71: 276-292, 2000.
34. Urtasun R, Latasa MU, Demartis MI, Balzani S, Goñi S, Garcia-Irigoyen O, Elizalde M, Azcona M, Pascale RM, Feo F, et al: Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology 54: 2149-2158, 2011.
35. Wang GB, Zhou XY, Yuan T, Xie J, Guo LP, Gao N and Wang XQ: Significance of serum connective tissue growth factor in patients with hepatocellular carcinoma and relationship with angiogenesis. World J Surg 34: 2411-2417, 2010.
36. Hirasaki S, Koide N, Ujike K, Shinji T and Tsuji T: Expression of Nov, CYR61 and CTGF genes in human hepatocellular carcinoma. Hepatol Res 19: 294-305, 2001.
37. Zeng ZJ, Yang LY, Ding X and Wang W: Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance. World J Gastroenterol 10: 3414-3418, 2004.
38. Xiu M, Liu YH, Brigstock DR, He FH, Zhang RJ and Gao RP: Connective tissue growth factor is overexpressed in human hepatocellular carcinoma and promotes cell invasion and growth. World J Gastroenterol 18: 7070-7078, 2012.
39. Komorowsky C, Ocker M and Goppelt-Struebe M: Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors. J Cell Mol Med 13: 2353-2364, 2009.
40. Schneider-Stock R and Ocker M: Epigenetic therapy in cancer: Molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors. IDrugs 10: 557-561, 2007.
41. Di Fazio P, Schneider-Stock R, Neureiter D, Okamoto K, Wissniowski T , Gahr S, Quint K, Meissnitzer M, Alinger B, Montalbano R, et al: The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis. Cell Oncol 32: 285-300, 2010.
42. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, et al: Combination therapy for hepatocellular carcinoma: Additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 56: 1343-1350, 2012.
43. Gahr S, Wissniowski T, Zopf S, Strobel D, Pustowka A and Ocker M: Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report. J Cancer 3: 158-165, 2012.
44. Di Fazio P, Montalbano R, Neureiter D, Alinger B, Schmidt A, Merkel AL, Quint K and Ocker M: Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res 318: 1832-1843, 2012.
45. Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T , Atadja P and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: The hydroxamic acid derivative LBH589. Clin Cancer Res 12: 634-642, 2006.
46. Ocker M: Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 1: 55-61, 2010.
47. Ellis L, Hammers H and Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-153, 2009.
48. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
49. Zuehlke J, Ebenau A, Krueger B and Goppelt-Struebe M: Vectorial secretion of CTGF as a cell-type specific response to LPA and TGF-β in human tubular epithelial cells. Cell Commun Signal 10: 25, 2012.
50. Saif MW: Anti-VEGF agents in metastatic colorectal cancer (mCRC): Are they all alike? Cancer Manag Res 5: 103-115, 2013.
51. Gahr S, Peter G, Wissniowski TT , Hahn EG, Herold C and Ocker M: The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines. Oncol Rep 20: 1249-1256, 2008.
52. Gahr S, Ocker M, Ganslmayer M, Zopf S, Okamoto K, Hartl A, Leitner S, Hahn EG and Herold C: The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. Int J Oncol 31: 567-576, 2007.
53. Budman DR, Tai J, Calabro A and John V: The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Invest New Drugs 29: 1224-1229, 2011.
54. Neri P, Bahlis NJ and Lonial S: Panobinostat for the treatment of multiple myeloma. Expert Opin Investig Drugs 21: 733-747, 2012.
55. Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR , Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson R M: TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms. Mol Oncol 8: 261-272, 2014.
56. Antonarakis ES and Carducci MA: Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets 16: 365-376, 2012.
57. Schweizer MT and Carducci MA: From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer. Cancer J 19: 99-106, 2013.
58. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, Yao Z, Dong XY, Zhao N and Liu N: CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triplenegative breast cancer. Oncogene 32: 544-553, 2013.
59. Zhang Y, Hong H, Nayak TR, Valdovinos HF, Myklejord DV, Theuer CP, Barnhart TE and Cai W: Imaging tumor angiogenesis in breast cancer experimental lung metastasis with positron emission tomography, near-infrared fluorescence, and bioluminescence. Angiogenesis 16: 663-674, 2013.
60. Aggarwal C, Somaiah N and Simon G: Antiangiogenic agents in the management of non-small cell lung cancer: Where do we stand now and where are we headed? Cancer Biol Ther 13: 247-263, 2012.
61. Xiao YY , Zhan P, Yuan DM, Liu HB , Lv TF, Song Y and Shi Y : Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: A meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 69: 151-159, 2013.
62. Pang R, Tse E and Poon RT: Molecular pathways in hepatocellular carcinoma. Cancer Lett 240: 157-169, 2006.
63. Ribatti D, Vacca A, Nico B, Sansonno D and Dammacco F: Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. Cancer Treat Rev 32: 437-444, 2006.
64. Zhang Q, Du Y, Xue Z, Chi C, Jia X and Tian J: Comprehensive evaluation of the anti-angiogenic and anti-neoplastic effects of Endostar on liver cancer through optical molecular imaging. PLoS One 9: e85559, 2014.
65. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438: 932-936, 2005.
66. Fischer C, Schneider M and Carmeliet P: Principles and therapeutic implications of angiogenesis, vasculogenesis and arteriogenesis. Handb Exp Pharmacol 176: 157-212, 2006.
67. Lin EY and Pollard JW: Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67: 5064-5066, 2007.
68. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H , Makino K, Ikeda E, Takata S, Kobayashi K and Okada Y : Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB?J 16: 219-221, 2002.
69. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E and Okada Y: Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 277: 36288-36295, 2002.
70. Shimo T, Nakanishi T, Kimura Y, Nishida T, Ishizeki K, Matsumura T and Takigawa M: Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells. J Biochem 124: 130-140, 1998.
71. Babic AM, Chen CC and Lau LF: Fisp12/mouse connective tissue growth factor mediates endothelial cell adhesion and migration through integrin alphavbeta3, promotes endothelial cell survival, and induces angiogenesis in vivo. Mol Cell Biol 19: 2958-2966, 1999.